… of clinical investigations involving VEGF inhibitors in the … of anti-VEGF therapy, monotherapy
with VEGF inhibitors in various … Suboptimal results in single-agent trials of VEGF inhibitors …

… cancer. Here we discuss the major angiogenic signaling pathway involving VEGF in prostate
cancer … analogs, tyrosine kinase inhibitors sorafenib and AZD2171, and other inhibitors of …

… Inhibiting the development of new blood vessels (antiangiogenesis) is a potential approach
to cancer therapy that has attracted interest in recent years. In theory, this approach should …

… inhibitors of the VEGF pathway approved for use in cancer … cytostatic effects of anti-VEGF
therapy. We review the current … for anti-cancer therapy using anti-VEGF agents, emphasizing …

… This study provided definitive proof that angiogenesis inhibitors could be effective in the
treatment of cancer, and based on the results of this study, the US Food and Drug Administration …

… of a therapeutic response to anti-VEGF treatment in human cancer is still poorly understood,
several concepts have been proposed to explain therapeutic failure of VEGF inhibition in …

… -B, and PIGF1 and 2, which has displayed efficacy in metastatic colorectal cancer (111).
Outside of RCC, VEGF inhibitors typically have limited activity as monotherapy and are …

… VEGF as a mediator of pathological angiogenesis. Anti-VEGF monoclonal antibodies and
other VEGF inhibitors block … Clinical trials with VEGF inhibitors in a variety of malignancies are …

… This comprehensive review discusses the limitations of inhibiting VEGF signaling alone
as an antiangiogenic strategy, the importance of other angiogenic pathways including PDGF/…

… VEGF inhibition is the humanized monoclonal antibody bevacizumab (Avastin ® ), which is
the only anti-angiogenic agent approved for treatment of cancer. … VEGF in cancer therapy has …